Natera CFO Maps Multiple Paths to $6 Billion Revenue Target by 2029
Natera's CFO outlined plans to reach $6B revenue by 2029, citing growth in Signatera testing, Medicare coverage, and new patient acquisition. Signatera revenue is expected to exceed $1B this year, with a 2029 price target of $1,450. Natera is investing in R&D and clinical trials, with a potential U.S. launch of its colorectal cancer screening test in 2028-2029. The company is also targeting the Japanese market for Signatera.
How this was made

The 30-second read
Why it matters
The CFO's roadmap provides the first public multi‑year revenue target, setting a new valuation baseline for the stock.
Market read
New guidance could attract growth‑oriented investors and influence sector sentiment toward MRD testing companies.
What to watch
Potential delays in FDA approval and Medicare coverage could dampen revenue growth.
Background
Natera is a diagnostics company focused on reproductive health, oncology and organ health, with its Signatera test central to its oncology portfolio.
Ticker impact
CFO outlines a $6 billion revenue target by 2029 and projects >$1 billion in Signatera revenue this year, providing fresh guidance.
potential upward pressure as investors price in higher revenue expectations
New multi‑year revenue target and near‑term $1 B forecast are primary disclosures not previously reported.
Market effects
Highlights growth potential in the MRD testing and early‑cancer detection sector.
U.S. diagnostics market may see increased investor interest.
Japan launch plans could add modest international exposure.
Counterpoint
Guidance may be overly optimistic; execution risk and reimbursement uncertainty could limit upside.
Key entities
- CompanyNatera, Inc.
Diagnostics firm providing genetic testing and molecular diagnostics.
- ExecutiveBrodie Brophy
Chief Financial Officer of Natera.


